ABL1 and neoplasm: Finally, the intriguing role of BCR-ABL/CK2 complex as being able to functionally inactivate the tumor suppressor PTEN may point to a highly effective proapoptotic therapy even in those cases characterized by TKI resistance due to BCR-ABL mutations.